ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression

Margot Lavy (1) , Vanessa Gauttier (1) , Alison Dumont (2) , Florian Chocteau (2) , Sophie Deshayes (2) , Judith Fresquet (2) , Virginie Dehame (2, 3, 4) , Isabelle Girault (1) , Charlène Trilleaud (1) , Stéphanie Neyton (1) , Caroline Mary (1) , Philippe Juin (2, 5) , Nicolas Poirier (1) , Sophie Barillé-Nion (2) , Christophe Blanquart (2)

1 OSE Immunotherapeutics [Nantes]
2 CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
3 CHU Nantes - Centre Hospitalier Universitaire de Nantes
4 Institut du Thorax [Nantes]
5 CRLCC René Gauducheau

Introduction. Tumor Associated Macrophages (TAM) are a major component of the tumor environment and their accumulation often correlates with poor prognosis by contributing to local inflammation, inhibition of anti-tumor immune response and resistance to anticancer treatments. In this study, we thus investigated the anti-cancer therapeutic interest to target ChemR23, a receptor of the resolution of inflammation expressed by macrophages, using an agonist monoclonal antibody, ChemR23. Methods. Human GM-CSF, M-CSF and Tumor Associated Macrophage (TAM)-like macrophages were obtained by incubation of monocytes from healthy donors with GM-CSF, M-CSF or tumor cell supernatants (Breast cancer (BC) or malignant pleural mesothelioma (MPM) cells). The effects of ChemR23 on macrophages were studied at the transcriptomic, protein and functional level. Datasets from The Cancer Genome Atlas (TCGA) were used to study CMKLR1 expression, coding for ChemR23, in BC and MPM tumors. In vivo, ChemR23 was evaluated on overall survival, metastasis development and transcriptomic modification of the metastatic niche using a model of resected triple negative breast cancer. Results. We show that ChemR23 is expressed at higher levels in M-CSF and tumor cell supernatant differentiated macrophages (TAM-like) than in GM-CSF-differentiated macrophages. ChemR23 activation triggered by ChemR23 deeply modulates M-CSF and TAM-like macrophages including profile of cell surface markers, cytokine secretion, gene mRNA expression and immune functions. The expression of ChemR23 coding gene (CMKLR1) strongly correlates to TAM markers in human BC tumors and MPM and its histological detection in these tumors mainly corresponds to TAM expression. In vivo, treatment with ChemR23 agonist increased mouse survival and decreased metastasis occurrence in a model of triple-negative BC in correlation with modulation of TAM phenotype in the metastatic niche. Conclusion. These results open an attractive opportunity to target TAM and the resolution of inflammation pathways through ChemR23 to circumvent TAM pro-tumoral effects.

Mots clés: ChemR23 receptor; agonist; antibody; cancer; macrophage

Domaines: Cancer

Margot Lavy, Vanessa Gauttier, Alison Dumont, Florian Chocteau, Sophie Deshayes, et al.. ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Frontiers in Immunology, 2023, 14, pp.3606 - 3619. ⟨10.3389/fimmu.2023.1196731⟩. ⟨inserm-04198031⟩